85 related articles for article (PubMed ID: 18383872)
1. Changes of immunological parameters reflect quality of life-related toxicity during chemotherapy in patients with advanced colorectal cancer.
Yoshimatsu K; Kuhara K; Itagaki H; Aizawa M; Yokomizo H; Fujimoto T; Otani T; Osawa G; Kobayashi R; Ogawa K
Anticancer Res; 2008; 28(1B):373-8. PubMed ID: 18383872
[TBL] [Abstract][Full Text] [Related]
2. Low-dose chemotherapy with leucovorin plus 5-fluorouracil for colorectal cancer can maintain host immunity.
Kobayashi R; Yoshimatsu K; Yokomizo H; Katsube T; Ogawa K
Anticancer Res; 2007; 27(1B):675-9. PubMed ID: 17348459
[TBL] [Abstract][Full Text] [Related]
3. [Assessment of quality of life by questionnaires between S-1/CPT-11 and mFOLFOX6 in patients with advanced colorectal cancer].
Tokunaga Y; Sasaki H; Matsueda S
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1127-31. PubMed ID: 21772096
[TBL] [Abstract][Full Text] [Related]
4. [Combination chemotherapy with S-1 plus CPT-11 for patients with advanced or recurrent colorectal cancer].
Tsunoda A; Nakao K; Kamiyama G; Narita K; Yamazaki K; Watanabe M; Suzuki N; Oonaka T; Kusano M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():135-7. PubMed ID: 16897989
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan and 5-FU/ leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics.
Hwang JJ
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):26-34. PubMed ID: 15685831
[TBL] [Abstract][Full Text] [Related]
6. [Progress in chemotherapy for colorectal cancer].
Sasaki T; Maeda Y
Gan To Kagaku Ryoho; 2000 Dec; 27(14):2185-92. PubMed ID: 11142161
[TBL] [Abstract][Full Text] [Related]
7. [Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer].
Goto A
Gan To Kagaku Ryoho; 2006 Jul; 33(7):896-900. PubMed ID: 16835475
[TBL] [Abstract][Full Text] [Related]
8. Effect of irinotecan on the phenotype of peripheral blood leukocyte populations in patients with metastatic colorectal cancer.
Melichar B; Touskova M; Vesely P
Hepatogastroenterology; 2002; 49(46):967-70. PubMed ID: 12143255
[TBL] [Abstract][Full Text] [Related]
9. [Controversy of treatment for advanced colorectal cancer--intermedisine].
Sato A; Shimada K; Taguchi S
Gan To Kagaku Ryoho; 2003 Sep; 30(9):1260-9. PubMed ID: 14518404
[TBL] [Abstract][Full Text] [Related]
10. [Second-line chemotherapy for advanced colorectal cancer].
Uetake H; Iida S; Tsunozaki H; Higuchi T; Yasuno M; Enomoto M; Sugihara K
Gan To Kagaku Ryoho; 2005 Jan; 32(1):24-7. PubMed ID: 15675577
[TBL] [Abstract][Full Text] [Related]
11. [S-1 as a single agent for colorectal cancer].
Eguchi T; Shirao K
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():121-4. PubMed ID: 16897986
[TBL] [Abstract][Full Text] [Related]
12. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.
Falcone A; Masi G; Allegrini G; Danesi R; Pfanner E; Brunetti IM; Di Paolo A; Cupini S; Del Tacca M; Conte P
J Clin Oncol; 2002 Oct; 20(19):4006-14. PubMed ID: 12351598
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.
Souglakos J; Vardakis N; Androulakis N; Kakolyris S; Kourousis C; Mavroudis D; Pallis A; Agelaki S; Kalbakis K; Georgoulias V
Dig Dis; 2007; 25(1):100-5. PubMed ID: 17384515
[TBL] [Abstract][Full Text] [Related]
15. Multicenter phase II study of CPT-11 fractionated over two days with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer.
Recchia F; Nuzzo A; Lalli A; Di Lullo L; De Filippis S; Saggio G; Di Blasio A; Rea S
Anticancer Res; 2003; 23(3C):2903-8. PubMed ID: 12926132
[TBL] [Abstract][Full Text] [Related]
16. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
Delaunoit T; Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Findlay BP; Thomas SP; Salim M; Schaefer PL; Stella PJ; Green E; Mailliard JA
Cancer; 2004 Nov; 101(10):2170-6. PubMed ID: 15470715
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.
Yamazaki K; Kuwano H; Ojima H; Otsuji T; Kato T; Shimada K; Hyodo I; Nishina T; Shirao K; Esaki T; Ohishi T; Denda T; Takeuchi M; Boku N
Cancer Chemother Pharmacol; 2015 Mar; 75(3):569-77. PubMed ID: 25575764
[TBL] [Abstract][Full Text] [Related]
18. A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma.
Gennatas C; Papaxoinis G; Michalaki V; Mouratidou D; Andreadis C; Tsavaris N; Pafiti A
J Chemother; 2006 Oct; 18(5):538-44. PubMed ID: 17127232
[TBL] [Abstract][Full Text] [Related]
19. Multicenter phase II study of irinotecan plus bolus fluorouracil/l-leucovorin for metastasic colorectal cancer.
Mishima H; Ikenaga M; Ishida H; Iwamoto S; Morimoto T; Narahara H; Kato T; Tsujie M; Kitai T; Fukunaga M; Nakanishi M; Tsujinaka T; Furukawa H; Taguchi T;
Anticancer Res; 2007; 27(2):1003-8. PubMed ID: 17465234
[TBL] [Abstract][Full Text] [Related]
20. Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer.
Nogué M; Salud A; Batiste-Alentorn E; Saigí E; Losa F; Cirera L; Méndez M; Campos JM; Galan A; Escudero P; Arcusa A; Manzano H; de Mendizábal EV; de Olaguer JP; Boleda M; Guasch I; Vicente P
Eur J Cancer; 2005 Oct; 41(15):2241-9. PubMed ID: 16214045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
